MinorClass III antiarrhythmics (Vaughan Williams)×Gabapentinoids (antiepileptics)
Updated · Methodology
Mechanism
Pregabalin undergoes negligible metabolism: less than 2% of a dose appears in the urine as metabolites and the rest is excreted unchanged by the kidneys. It does not bind to plasma proteins and does not inhibit drug metabolism in vitro. According to its SmPC, it is unlikely to cause or be subject to pharmacokinetic interactions (pregabalin SmPC, European Medicines Agency, EMA, sections 4.5 and 5.2). Amiodarone is metabolised in the liver by CYP3A4 and CYP2C8 to active desethylamiodarone, is eliminated mainly in bile and faeces, and itself inhibits CYP3A4, CYP2C9, CYP2D6 and P-gp (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). Pregabalin does not depend on these enzymes or on P-gp, so their inhibition by amiodarone does not affect it.
Symptoms
The documents describe no symptoms caused by this combination. Pregabalin causes dizziness and somnolence, which can increase the risk of falls in older people. Loss of consciousness and confusion have been reported after marketing (pregabalin SmPC, European Medicines Agency, EMA, section 4.4). Amiodarone commonly slows the heart rate in a dose-dependent way, and hyperthyroidism caused by it can develop even several months after stopping (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4 and 4.8).
Management
According to the documents, the combination is acceptable and no dose change of amiodarone or pregabalin is needed. Neither document names the pair, and pregabalin belongs to none of the classes that call for caution with amiodarone: drugs that prolong the QT interval, lower potassium or slow the heart rate (pregabalin SmPC, European Medicines Agency, EMA; amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). People taking pregabalin are advised to be careful until they know how it affects them. In renal impairment, the pregabalin dose is reduced according to creatinine clearance (pregabalin SmPC, EMA, sections 4.2, 4.4 and 5.2). Amiodarone continues to be eliminated for several months after stopping, and its effect persists for 10 days to one month (amiodarone SmPC, AEMPS, section 5.2).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Amiodarona, Trangorex 200 mg (nº registro 48048), secciones 4.3, 4.4 y 4.5 (2022)– AEMPS, CIMA, nº registro 48048, revisión 08/2022, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Pregabalina (EU/1/04/279), secciones 4.4 y 4.5 (2024)– EMA, ficha técnica de Lyrica en CIMA (nº registro 104279015), revisión del texto 05/2024, secciones 4.4 y 4.5